Showing results (41-50 of 48) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 48 results.
Metabolism: Clinical and Experimental|March 27, 1999
Improved glucose tolerance in rats treated with the dipeptidyl peptidase IV (CD26) inhibitor Ile-thiazolidideR P Pauly, H U Demuth, F Rosche, et al.
Diabetes|March 28, 2002
Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and beta-cell glucose responsiveness in VDF (fa/fa) Zucker ratsJ A Pospisilik, S G Stafford, H-U Demuth, et al.
The Journal of Biological Chemistry|February 8, 2000
Dipeptidyl peptidase IV (DPIV/CD26) degradation of glucagon. Characterization of glucagon degradation products and DPIV-resistant analogsS A Hinke, J A Pospisilik, H U Demuth, et al.
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences|August 29, 2001
Effect of aging and diabetes on the enteroinsular axisJ Korosi, C H McIntosh, R A Pederson, et al.
Scandinavian Journal of Immunology|February 1, 1989
Dipeptidyl peptidase IV in human T lymphocytes. Impaired induction of interleukin 2 and gamma interferon due to specific inhibition of dipeptidyl peptidase IVE Schön, H U Demuth, E Eichmann, et al.
Neuropeptides|December 9, 1998
Intrathecal administration of p-hydroxymercuribenzoate or phosphoramidon/bestatin-combined induces antinociceptive effects through different opioid mechanismsK Tan-No, A Taira, M Inoue, et al.
Diabetes, Obesity & Metabolism|February 18, 2005
Improvement of glucose tolerance in Zucker diabetic fatty rats by long-term treatment with the dipeptidyl peptidase inhibitor P32/98: comparison with and combination with rosiglitazoneE Wargent, C Stocker, P Augstein, et al.
Neurobiology of Disease|December 3, 2013
Disrupted cross-laminar cortical processing in β amyloid pathology precedes cell deathH Lison, M F K Happel, F Schneider, et al.
Pageof 5